Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Induced Pluripotent-Stem Cells Have Untapped Potential for Disease Treatment

By LabMedica International staff writers
Posted on 06 Sep 2011
A recent publication reviewed progress made over the past several years in applying induced pluripotent-stem cell (iPSC) technology to the treatment of human diseases such as Parkinson's disease, Alzheimer's disease, and cardiovascular disease.

iPSCs were first produced in 2006 from mouse cells and in 2007 from human cells. More...
In principle, the use of iPSCs presents several attractive alternatives to the use of human embryonic stem cells. In particular, use of iPSCs avoids the ethical dilemma surrounding the use of human embryonic cells. Also, the use of an individual’s own cells should eliminate or reduce the risk of rejection by the immune system.

Investigators at the University of California, Davis (USA) examined the difficulties that have arisen to prevent the widespread clinical use of iPSCs.

The reported in the August 5, 2010, issue of the journal Cell Stem Cell that while the pluripotent nature of iPSCs allows them to transform into mature cell types such as neurons, they also possess a serious potential for generating tumors. In addition, at least one study reported immune rejection of transformed by iPSCs by a patient who had provided the cells initially.

Nonetheless, the investigators feel that iPSCs remain a major untapped resource for treatment of certain diseases. “iPSCs offer the potential to treat many diseases as an alternative or adjuvant therapy to drugs or surgery,” said senior author Dr. Paul S. Knoepfler, associate professor of cell biology and human anatomy at the University of California, Davis. “Problems that have been identified with their use likely can be overcome, allowing iPSCs to jump from the laboratory dish to patients who could benefit from them. Future studies of iPSCs should increasingly focus on issues most relevant to the eventual clinical use of the cells, offering the fastest pathway to treating patients with this potentially powerful therapeutic tool.”

Related Links:

University of California, Davis



Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
ESR Analyzer
TEST1 2.0
Capillary Blood Collection Tube
IMPROMINI M3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.